AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-06

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

NCT04368182

Hepatocellular Carcinoma

UNKNOWN PHASE1

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

NCT03672305

Primary Hepatocellular Carcinoma

UNKNOWN EARLY_PHASE1

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

NCT03349255

Hepatocellular Carcinoma Liver Cancer Liver Neoplasms +1 more

TERMINATED PHASE1

HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

NCT06515314

Hepatic Cell Carcinoma

RECRUITING PHASE1

TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

NCT03899415

Hepatocellular Carcinoma

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study plans to enroll 9 patients to assess the safety of C-TCR055. Subjects who meet the eligibility criteria will receive a single dose of C-TCR055 injection, and will be followed up post treatment for safety monitoring. The follow up period will last 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

C-TCR055

Autologous C-TCR055 administered by intravenous (IV) infusion

Group Type EXPERIMENTAL

AFP Specific T Cell Receptor T Cells

Intervention Type BIOLOGICAL

Autologous T cells transduced with lentivirus encoding AFP specific TCR gene

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AFP Specific T Cell Receptor T Cells

Autologous T cells transduced with lentivirus encoding AFP specific TCR gene

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to provide written informed consent.
2. Age 18-70 years old, male or female.
3. Patients must meet the following criteria:

1. Histologically confirmed HCC
2. Serum AFP \>200 ng/mL
3. Child-Pugh score ≤6
4. BCLC stage B and stage C or stage Ⅱa/Ⅱb and Ⅲa/Ⅲb defined by Chinese Liver Cancer Guideline（2017）
5. Clinical confirmed relapse or progression if patient had locoregional therapy previously
6. Systemic therapy failed HCC Subject: those who received standardized systemic treatment for unresectable HCC and subsequently relapsed/progressed, or were intolerable or unwilling to receive treatment. Front-line system treatment should be approved in China (sorafenib, lenvastinib, platinum-containing chemotherapy regimen, regofinil)
7. . Local treatment (including surgery, ablation, interventional therapy, local radiotherapy, etc.) must be completed at least 4 weeks before apheresis, and there is no unhealed wound.
8. Previous systemic therapy was discontinued at least 2 weeks before apheresis.
4. Has at least 1 measurable lesion as defined per RECIST v1.1.
5. HLA-A 02:01 allele positive.
6. Liver AFP expression IHC tests:

1. ≥20% tumor cells positive, and ≤5% non-tumor tissue positive;
2. serum AFP ≥400ng/ml, and ≤5% non-tumor tissue positive.
7. ECOG score ≤ 1.
8. Expected survival \> 12 weeks
9. Left ventricular ejection fraction (LVEF) ≥ 50% (measured by echocardiography).
10. No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.
11. Laboratory criteria

1. Absolute neutrophil count (ANC) ≥ 1.5x10\^9/ L
2. Platelets≥ 60x10\^9/L
3. Hemoglobin≥ 90g/L
4. Serum total bilirubin ≤ 2 x ULN
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 x ULN
6. Creatinine ≤1.5×ULN
7. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN
12. If patient has previous HBV infection, patient should receive antivirals treatment following treatment guidelines during study period, and the HBV DNA copies should below the detection limit at screening.
13. Female subjects in childbearing age, their serum or urine pregnancy test must be negative, all subjects must agree to take effective contraceptive measures during the trial.
14. Agree to abstain from alcohol during the study period
15. No contraindications for apheresis
16. Apheresis was received by laboratory ,and passed QC

Exclusion Criteria

1. Have a history of allergy to cellular products.
2. Subject has liver transplantation history.
3. tumor volume was greater than 70% of liver tissue
4. main portal vein carcinoma thrombus
5. Medium to severe ascites.
6. subjects received other anti-tumor systemic therapy except standard systemic therapy. Or subjects received immunocheckpoint inhibitors was less than 6 weeks or 2 drug half-lives.
7. Subject has other primary cancer except for the following:

A. Non-melanoma cured by excision, such as basal cell skin cancer. B. Cured in situ cancers such as cervical cancer, bladder cancer or breast cancer
8. Significant clinical gastrointestinal bleeding within 4 weeks before treatment.
9. Subjects with bone metastasis or central nervous system metastasis, or with hepatic encephalopathy, epilepsy, cerebrovascular accident and other central nervous system involvement diseases.
10. Prior treatment with genetically modified T cell therapy or stem cell therapy.
11. Uncontrolled active infection. Preventive antibiotics, antiviral and antifungal are permitted.
12. Active hepatitis virus infection. HCV RNA positive.
13. Subjects with syphilis or other acquired, congenital immunodeficiency disorders, including, but not limited to, HIV infected persons, systemic lupus erythematosus, psoriasis, etc.
14. Heart insufficiency subjects of Grade III or IV according to NYHA classification criteria.
15. Subjects received systemic therapeutic steroid doses (except for the recent or current use of inhaled steroids) or other immunotherapy (such as interleukin-interferon, thymosin, etc.) within 2 weeks before Leukocyte apheresis.
16. Subjects received radiotherapy within 6weeks before Leukocyte apheresis
17. Subjects who are pregnant, lactating, or pregnant within 6 months
18. Any other disease that may increase the risk of the subject or interfere with the results of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No